TWST: AI Drug Discovery Hopes Will Outrun Earnings Execution Risk

The analyst price target for Twist Bioscience has been revised higher to $64.38 from $63.33. Analysts point to updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E as key drivers of the change.

Analyst Commentary

Recent Street research on Twist Bioscience has leaned toward higher price targets and upgraded views, with multiple firms revisiting their models around fair value, discount rates, growth assumptions and future P/E. For you as an investor, the key is understanding what analysts like about the story and where they still see execution or valuation risk.

Bullish Takeaways

Bullish analysts are lifting price targets, suggesting they see the updated fair value framework as more supportive of the current long term growth narrative for Twist Bioscience.
Several of the new reports refer to higher price targets in increments of US$4 to US$15, which indicates that the underlying revisions to revenue and margin assumptions are material enough to move modeled equity value.
Upgrades in rating, not just target tweaks, signal growing confidence that the company can execute on its plan well enough for earnings and future P/E assumptions to align with the revised valuation work.
The clustering of positive revisions over a relatively short period points to a broad recheck of models, with analysts appearing more comfortable with the risk and reward profile after updating discount rates and long term growth inputs.

Bearish Takeaways

Even with higher targets, the need for repeated recalibration of fair value and discount rate assumptions highlights that the investment case is sensitive to small shifts in growth and profitability expectations.
The use of higher future P/E assumptions in several reports means a portion of the valuation rests on confidence in long term execution, which can be vulnerable if revenue or margin trends do not align with current forecasts.
Target changes clustered around US$4 to US$15 suggest that while sentiment has improved, analysts are still refining their models rather than making wholesale changes, which can indicate lingering caution on how quickly Twist Bioscience can deliver against expectations.
Investors should treat the upgraded targets as one input rather than a roadmap, since the research itself underscores that fair value for the stock can move meaningfully when analysts revisit core growth and profitability assumptions.

What's in the News

Guggenheim raised its price target on Twist Bioscience to US$60 from US$55 after fiscal Q2 2026 results that included 19% year over year revenue growth across DNA Synthesis, Protein Solutions, and NGS Applications. The company lifted its full year outlook, citing expectations for continued revenue growth, gross margin expansion and an approach toward adjusted EBITDA breakeven in Q4 FY 2026 (source: Guggenheim).
Twist Bioscience launched an early access Complex Genes offering, expanding its clonal gene portfolio to support structurally complex DNA sequences up to 7,000 base pairs and targeting approximately 99.5% of clonal gene orders and 99.9% of all DNA products. The offering is aimed at applications including AI powered drug discovery and nucleic acid therapeutics development (source: company announcement).
Leerink raised its price target on Twist Bioscience to US$80 from US$70 following the company’s Investor Day, highlighting management’s expectations for revenue of about US$1b by fiscal 2031, adjusted EBITDA profitability starting in fiscal 2027 and long term gross margins above 60% (source: Leerink).
Twist Bioscience entered a collaboration with LenioBio to integrate LenioBio’s ALiCE cell free protein expression platform with Twist’s DNA manufacturing and automation capabilities, with the aim of speeding up design build test cycles and supporting higher throughput protein expression services for customers’ AI models (source: company announcement).

Valuation Changes

Fair Value: revised modestly higher from $63.33 to $64.38 per share.
Discount Rate: adjusted from 7.15% to 7.15%, reflecting a very small change in the rate used to discount future cash flows.
Revenue Growth: updated from 15.76% to 16.13%, indicating a small upward shift in expected top line expansion.
Net Profit Margin: refined from 18.87% to 19.04%, pointing to a slightly stronger long term profitability assumption.
Future P/E: moved marginally from 44.20x to 44.11x, suggesting a nearly unchanged view of the multiple applied to future earnings.

9 views

Key Takeaways

Broadening customer base, innovative product launches, and industry tailwinds are driving sustained growth and widening Twist's market opportunity.
Increased operational efficiency, product diversification, and global market trends support expanding margins and improved long-term earnings stability.
Heavy customer concentration, ongoing losses, volatile margins, and stagnant emerging market growth threaten revenue stability, profitability, and long-term competitive positioning in dynamic genomics markets.

Catalysts

About Twist Bioscience

Manufactures and sells synthetic DNA-based products.What are the underlying business or industry changes driving this perspective?

Expansion of Twist's customer base, especially among smaller academic clients and long-tail customers, combined with the successful rollout of new synthetic biology (SynBio) product lines, is likely to drive sustained top-line growth and broaden the company's addressable market, positively impacting future revenue.
High demand from large pharma, biotechnology, and clinical diagnostic customers for personalized medicine, genomics, and next-generation sequencing (NGS) services continues to accelerate, supported by long-term increases in global life sciences R&D investment, which should fuel ongoing revenue growth and earnings stability.
Continuous product innovation, including new gene fragment offerings and anticipated upcoming product launches, reflects strategic reinvestment into R&D and manufacturing infrastructure, supporting scalability and improved gross margins over the medium to long term.
Significant improvements in gross margin (now above 50%) through volume leverage, process improvements, and increased vertical integration signal ongoing margin expansion and a clear near-term path toward adjusted EBITDA breakeven, indicating robust future earnings potential.
Diversification across multiple end markets and geographies, coupled with strong underlying industry trends like AI-driven drug discovery and global genomics market expansion, provides resilience against market cycles and supports steady, long-term revenue and profit growth.

Twist Bioscience Earnings and Revenue Growth

Twist Bioscience Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Twist Bioscience's revenue will grow by 16.1% annually over the next 3 years.
Analysts are not forecasting that Twist Bioscience will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Twist Bioscience's profit margin will increase from -19.8% to the average US Biotechs industry of 19.0% in 3 years.
If Twist Bioscience's profit margin were to converge on the industry average, you could expect earnings to reach $122.1 million (and earnings per share of $1.79) by about June 2029, up from -$81.3 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 44.3x on those 2029 earnings, up from -55.4x today. This future PE is greater than the current PE for the US Biotechs industry at 16.4x.
Analysts expect the number of shares outstanding to grow by 3.16% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.15%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Twist Bioscience remains unprofitable, with an expected adjusted EBITDA loss of $45 million to $47 million for fiscal 2025, and only a goal-not a guarantee-to achieve breakeven in 2026; persistent negative operating margins increase the risk of future dilution or an eventual capital raise, which could weigh on earnings per share and shareholder value over time.
A substantial portion of NGS (Next-Generation Sequencing) revenue is concentrated with a small number of large customers-44% of NGS revenue comes from just the top 10 customers-meaning revenue could be volatile or contract sharply if any of these relationships weaken or are lost, posing a risk to recurring revenue stability and overall top line growth.
The company's guidance and margin improvements partly benefited from favorable order timing and mix in recent quarters, which may not repeat; this creates uncertainty about true underlying margin expansion and raises concerns over the sustainability of gross margins and predictable revenue growth into future periods.
Intense competition and potential commoditization in both the NGS and SynBio markets are acknowledged, especially as the company broadens market access and pursues smaller accounts or academic/government customers; this could lead to downward pricing pressure, compress gross margins, and limit future profitability as competition intensifies or innovation outpaces the company's offerings.
Growth in the APAC region remains stagnant and total revenue exposure to China is minimal (approximately 1.5% of Q3 revenue), limiting Twist's ability to capitalize on the rapid expansion of genomics markets in major emerging economies, which may restrict long-term revenue diversification and growth opportunities compared to industry peers who succeed in these markets.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $64.38 for Twist Bioscience based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $80.0, and the most bearish reporting a price target of just $36.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $641.4 million, earnings will come to $122.1 million, and it would be trading on a PE ratio of 44.3x, assuming you use a discount rate of 7.2%.
Given the current share price of $72.33, the analyst price target of $64.38 is 12.4% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Twist Bioscience?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

TWST: Share Valuations Will Stabilize As End Markets Remain Strong